Caprock Group’s Haemonetics HAE Stock Holding History

Caprock Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,270	Closed	-$260K	–	380
2018 Q3	$260K	Sell	2,270 -1,324	-37%	-$137K	0.05%	304
2018 Q2	$322K	Sell	3,594 -85	-2%	-$7.18K	0.07%	267
2018 Q1	$269K	Buy	+3,679	New	+$252K	0.06%	306

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caprock Group's HAE Position: Q4 2018 in Review

Caprock Group sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 2,270 shares — an estimated $260K sold.

Caprock Group first reported a position in HAE in Q1 2018 and held it in 3 quarters. The position peaked at $322K in Q2 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

Caprock Group reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
Caprock Group sold 2,270 Haemonetics shares in Q4 2018, an estimated $260K.
Caprock Group first reported a position in Haemonetics in Q1 2018 and held it in 3 quarters.
Caprock Group's Haemonetics position peaked at $322K in Q2 2018.
279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Caprock Group's 13F filing for Q4 2018, filed 29 Jan 2019.